E2 concludes enrolment of pulmonary embolism thrombectomy system trial

RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)

Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. New Britain, PA June 25, 2025 --(PR.com)-- NeThrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication…

Endovascular Engineering's ENGULF pivotal trial completes patient enrolment - Interventional News

Endovascular Engineering (E2) has completed patient enrolment in the pivotal cohort of its ENGULF trial, involving the Hēlo pulmonary embolism (PE) thrombectomy system. The investigational device exemption study was carried out at 19 interventional cardiology, radiology, and vascular surgery centres in the USA. E2’s system features a patented dual-action mechanism that combines aspiration with clot disruption. It is designed to treat PE, a serio…

E2 concludes enrolment of pulmonary embolism thrombectomy system trial

E2 has completed enrolment of subjects in the pivotal cohort of its ENGULF trial, involving the Hēlo PE Thrombectomy System.The post E2 concludes enrolment of pulmonary embolism thrombectomy system trial appeared first on Medical Device Network.